The ATP6V1G2 Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population derived from the HeLa cell line, in which the ATP6V1G2 gene has been disrupted to generate a loss-of-function model. This product provides a heterogeneous pool of knockout cells suitable for functional studies without clonal selection, enabling robust investigation of V-ATPase-dependent processes.
HeLa cells, originating from a human cervical adenocarcinoma, are HPV18-positive and exhibit p53 inactivation via the E6 oncoprotein, along with constitutive telomerase activity. These epithelial cells are widely employed as a model system in cancer biology and cell cycle studies, offering a well-characterized platform for assessing the impact of gene disruptions on fundamental cellular pathways.
ATP6V1G2 encodes subunit G2 of the V1 domain of vacuolar ATPase (V-ATPase), a multi-subunit complex that pumps protons using ATP hydrolysis to acidify organelles. This subunit is critical for V1 domain assembly and coupling ATP hydrolysis to proton translocation. Within the signaling network, V-ATPase-mediated acidification regulates mTORC1 activation at the lysosomal surface by controlling Rag GTPase nucleotide loading. mTORC1 subsequently phosphorylates transcription factor EB (TFEB), retaining it in the cytoplasm; upon V-ATPase inhibition, TFEB translocates to the nucleus to drive lysosomal biogenesis and autophagy. Knockout of ATP6V1G2 disrupts these regulatory loops, impairing cathepsin activation, autophagic flux (evidenced by altered LC3B-II lipidation and p62 accumulation), and endocytic trafficking. Interacting partners include V1 subunits ATP6V1A and ATP6V1B2, the V0 a-subunit, the RAVE assembly complex, and accessory protein ATP6AP1. Upstream regulators such as hypoxia-inducible factor 1 alpha (HIF1A) and glucose availability modulate V-ATPase activity, positioning ATP6V1G2 at an integration point for metabolic and stress signals.
In the HeLa background, where aberrant pH regulation contributes to cancer progression, ATP6V1G2 knockout offers a tool to dissect how V-ATPase dysfunction affects cellular adaptation. HeLa cells depend on lysosomal acidification for mTORC1 signaling and autophagy; loss of V1G2 impairs these pathways, potentially altering proliferation and drug sensitivity. Given the HPV-positive, p53-inactivated state, this model enables examination of viral oncoprotein interactions with V-ATPase-dependent trafficking and degradation. Moreover, it facilitates study of altered lysosomal sequestration of chemotherapeutics, providing insights into multidrug resistance mechanisms.
Typical research applications encompass immunofluorescence detection of LC3 and p62 to monitor autophagy, LysoTracker staining to assess acidic organelles, and cathepsin activity assays for lysosomal proteolysis. mTORC1 pathway status can be evaluated by phospho-S6K1 western blotting, while drug sensitivity assays (e.g., with doxorubicin) reveal impacts on chemoresistance. Endocytosis can be measured via fluorescein-dextran uptake. Thus, the ATP6V1G2 Knockout HeLa Polyclonal Cells serve as a versatile platform for cancer research, autophagy studies, and V-ATPase functional analysis. For further information, contact Ascent Research.
